Phase 4Active, not recruiting
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes (SURPASS-EARLY)
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
- Sponsor
- Eli Lilly and Company (Industry)
- Enrollment
- 794 enrolled
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide; Antihyperglycemic medication
- Ages
- adults, older adults
- Registry
- NCT05433584, CTIS2022-501073-40-00, EUCTR2022-000130-42
Full record on ClinicalTrials.gov
From the registry
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
Primary outcomes
- Change From Baseline in Hemoglobin A1c (HbA1c)
History
Study completion expected
Results posted
Last registry update
Primary completion
Started
Registered